NCT05257083 2026-03-17
CARTITUDE-6
European Myeloma Network B.V.
Phase 3 Active not recruiting
Clinical Trials
74 trialsNCT05438043 2026-03-16
A Study of Daratumumab
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT03901963 2026-03-13
AURIGA
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04923893 2026-03-13
CARTITUDE-5
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05827016 2026-03-13
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
Bristol-Myers Squibb
Phase 3 Recruiting
NCT05552222 2026-03-12
MajesTEC-7
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06045806 2026-03-05
KarMMa-9
Celgene
Phase 3 Active not recruiting
NCT03729804 2026-03-04
(COBRA)
University of Chicago
Phase 3 Active not recruiting
NCT05623020 2026-03-04
MagnetisMM-6
Pfizer
Phase 3 Recruiting
NCT00602641 2026-03-03
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04566328 2026-03-02
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT05804032 2026-02-18
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
Phase 3 Completed
NCT05243797 2026-02-17
MajesTEC-4
European Myeloma Network B.V.
Phase 3 Recruiting
NCT03710603 2026-02-10
Perseus
European Myeloma Network B.V.
Phase 3 Active not recruiting
NCT03617731 2026-02-03
Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)
University of Heidelberg Medical Center
Phase 3 Active not recruiting
NCT07297329 2026-01-29
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Sinocelltech Ltd.
Phase 3 Recruiting
NCT06932562 2026-01-23
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
European Myeloma Network B.V.
Phase 3 Recruiting
NCT01208662 2026-01-22
DFCI 10-106
Dana-Farber Cancer Institute
Phase 3 Active not recruiting
NCT03652064 2026-01-20
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT06679101 2026-01-08
DREAMM-10
GlaxoSmithKline
Phase 3 Recruiting
NCT01208766 2026-01-06
HO95
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Completed
NCT05317416 2025-12-22
MagnetisMM-7
Pfizer
Phase 3 Active not recruiting
NCT07285239 2025-12-16
PrE1005
PrECOG, LLC.
Phase 3 Not yet recruiting
NCT04270409 2025-12-12
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
Sanofi
Phase 3 Active not recruiting
NCT02252172 2025-10-20
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT04071457 2025-09-15
DRAMMATIC
SWOG Cancer Research Network
Phase 3 Active not recruiting
NCT03993912 2025-09-11
IFM2017_03
University Hospital, Lille
Phase 3 Active not recruiting
NCT01863550 2025-09-08
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT05561387 2025-06-04
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
SWOG Cancer Research Network
Phase 3 Recruiting
NCT03941860 2025-05-23
Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial
National Cancer Institute (NCI)
Phase 3 Completed
NCT02076009 2025-05-01
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT04096066 2025-01-15
KRdvsRd
Fondazione EMN Italy Onlus
Phase 3 Active not recruiting
NCT03836014 2024-12-06
CONFIRM
Assistance Publique - Hôpitaux de Paris
Phase 3 Active not recruiting
NCT03319667 2024-11-27
IMROZ
Sanofi
Phase 3 Active not recruiting
NCT01093196 2024-11-07
Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients
Fondazione EMN Italy Onlus
Phase 3 Completed
NCT04934475 2024-11-07
MIDAS
Intergroupe Francophone du Myelome
Phase 3 Active not recruiting
NCT01091831 2024-11-06
Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects
Fondazione EMN Italy Onlus
Phase 3 Completed
NCT06187441 2024-08-19
HOVON174MM
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Recruiting
NCT03859427 2024-08-13
ARROW2
Amgen
Phase 3 Completed
NCT00551928 2024-07-22
MPRvsMEL200
Fondazione EMN Italy Onlus
Phase 3 Completed
NCT03952091 2024-07-03
TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
TJ Biopharma Co., Ltd.
Phase 3 Completed
NCT02516696 2023-06-05
BiRd vs Rd
Weill Medical College of Cornell University
Phase 3 Terminated
NCT03948035 2023-05-06
Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM
Wuerzburg University Hospital
Phase 3 Active not recruiting
NCT01685814 2023-04-27
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
Wuerzburg University Hospital
Phase 3 Unknown
NCT05802992 2023-04-07
The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients
Affiliated Hospital of Nantong University
Phase 3 Unknown
NCT01564537 2023-03-10
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Takeda
Phase 3 Completed
NCT01090089 2023-02-23
DSM XIII
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Phase 3 Completed
NCT03651128 2022-12-15
KarMMa-3
Celgene
Phase 3 Active not recruiting
NCT01335399 2022-09-30
ELOQUENT - 1
Bristol-Myers Squibb
Phase 3 Completed
NCT01239797 2022-06-01
ELOQUENT - 2
Bristol-Myers Squibb
Phase 3 Completed